Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799541 | 1.00 | NPC1 (0.46) | NPC1LMNATSHRABCB1POLB | |
| SCHEMBL14404525 | 0.94 | NPC1 (0.46) | NPC1ABCB1POLBPPM1B | |
| SCHEMBL8669182 | 0.94 | NPC1 (0.46) | NPC1ABCB1POLBPPM1B | |
| SCHEMBL7902225 | 0.94 | NPC1 (0.46) | NPC1ABCB1POLBPPM1B | |
| SCHEMBL14593729 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 | |
| SCHEMBL4858609 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 | |
| SCHEMBL29329361 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 | |
| SCHEMBL5385400 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 | |
| SCHEMBL4613728 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 | |
| SCHEMBL14627118 | 0.92 | NPC1 (0.49) | NPC1LMNAPOLBPPM1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | NPC1 398/4885LMNA 742/4885TSHR 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.